标题:Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy
作者:Gao, Shuai; Li, Xiaoyang; Zang, Jie; Xu, Wenfang; Zhang, Yingjie
作者机构:[Gao, Shuai; Li, Xiaoyang; Zang, Jie; Xu, Wenfang; Zhang, Yingjie] Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, 44 West Culture Rd, Jinan 250012, 更多
通讯作者:Xu, WF;Zhang, YJ
通讯作者地址:[Xu, WF; Zhang, YJ]Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, 44 West Culture Rd, Jinan 250012, Shandong, Peoples R China.
来源:ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
出版年:2017
卷:17
期:6
页码:802-812
DOI:10.2174/1871520616666160901150427
关键词:Epigenetic; histone deacetylase inhibitors; chidamide; hematologic and; solid cancers; preclinical and clinical trials
摘要:Epigenetic modifications play central roles in cellular differentiation and their deregulations really contribute to tumor development. Histone deacetylase (HDAC) enzymes can exert their functions in the epigenetic regulation of gene expression related to oncogenesis via deacetylating the lysine residues of histones in the chromatin and various non-histone proteins. A majority of HDAC inhibitors (HDACIs) have been in different stages of preclinical and clinical trials with potent anticancer activity recently. Among these agents, chidamide tested as either monotherapeutic agent or in combination regimens for numerous hematological and solid malignancies has shown promising potential as an orally active subtype-selective HDACI. Herein we will highlight the progress of clinical trials of chidamide and rationally analyze those results from both preclinical and clinical studies about chidamide as an epigenetic modulator in cancer therapy.
收录类别:SCOPUS;SCIE
WOS核心被引频次:1
Scopus被引频次:1
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85025137612&doi=10.2174%2f1871520616666160901150427&partnerID=40&md5=697b10147eb9c5f7f1185f8ae0e2462d
TOP